OTCM
LMMY
Aug 21, Last price
0.17USD
1Q
-64.13%
IPO
-17.50%
Name
LAMY
Chart & performance
P/E
—
P/S
—
EPS
0.01
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
4k
-67.39%
Net income
51k
P
CFO
-5k
L-88.12%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Exousia Bio, Inc. is a biotechnology company that designs, develops, and manufactures mammalian- and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company's platform enables the custom production of exosomes with enhanced genetic functionality that can selectively target specific cells to address diseases. The company was formerly known as LAMY and changed its name to Exousia Bio, Inc. in January 2026.
Valuation
Title in thousands, except ratios and share amounts | FY | FY | FY |
|---|---|---|---|
| 2025‑05 | 2024‑05 | 2023‑05 | |
| Income | |||
Revenues | |||
Cost of revenue | |||
Unusual Expense (Income) | |||
NOPBT | |||
NOPBT Margin | |||
Operating Taxes | |||
Tax Rate | |||
NOPAT | |||
Net income | |||
Dividends | |||
Dividend yield | |||
Proceeds from repurchase of equity | |||
BB yield | |||
| Debt | |||
Debt current | |||
Long-term debt | |||
Deferred revenue | |||
Other long-term liabilities | |||
Net debt | |||
| Cash flow | |||
Cash from operating activities | |||
CAPEX | |||
Cash from investing activities | |||
Cash from financing activities | |||
FCF | |||
| Balance | |||
Cash | |||
Long term investments | |||
Excess cash | |||
Stockholders' equity | |||
Invested Capital | |||
ROIC | |||
ROCE | |||
| EV | |||
Common stock shares outstanding | |||
Price | |||
Market cap | |||
EV | |||
EBITDA | |||
EV/EBITDA | |||
Interest | |||
Interest/NOPBT |